MC2 Therapeutics has announced a collaboration agreement with EPI Health on the commercialization of WYNZORA Cream in the US.
WYNZORA Cream was approved by the U.S. Food and Drug Administration (FDA) on July 20th, 2020 for the topical treatment of plaque psoriasis in adults, 18 years of age or older.
“The upcoming launch of WYNZORA Cream, in the US, will bring an important new treatment experience to people with plaque psoriasis that will set a new standard. WYNZORA Cream is an excellent example of how our PAD Technology can bring value to all key stakeholders – patients, physicians and payers alike,” says Jesper J. Lange, CEO of MC2 Therapeutics. “Since Phase 3 data read-out we have planned for a strong market entry and launch of WYNZORA Cream in the US. We are very excited to have the opportunity to accelerate the roll-out through a partnership with EPI Health. Under the leadership of its President, John Donofrio, EPI Health has built a culture of excellence in commercialization of dermatological drugs. Combined with its strong commitment to WYNZORA Cream and our shared corporate values – this is a timely and perfect match for WYNZORA Cream, MC2 Therapeutics and EPI Health.”
Terms of the agreement
MC2 Therapeutics retains full ownership of WYNZORA Cream under the collaboration agreement and MC2 Therapeutics and EPI Health will utilize their combined resources to make WYNZORA Cream a leading patient preferred topical treatment of psoriasis in the US. EPI Health will utilize its commercial infrastructure to promote and sell WYNZORA Cream in return of a share of net sales.
MC2 Therapeutics has submitted its Marketing Authorization Application for WYNZORA Cream in EU in June 2020.
Photo of Jesper Lange: MC2 Therapeutics